Corticosteroids use can cause raised intraocular pressure (IOP), leading to glaucoma. We present a case report of steroid induced glaucoma in a young male with keratoconjunctivitis (VKC). Our patient was uncompliant with instructions to stop steroid use, initially started for VKC treatment, and required aggressive medical and surgical intervention for IOP control. He eventually progressed to severe glaucomatous optic neuropathy and eventual tunnel vision. Steroid induced glaucoma is an important and frequently encountered condition in ophthalmology clinics. This report serves to remind all physicians of the dangers of steroid eye drop usage.
INtRODUctION
Vernal keratoconjunctivitis is a chronic, allergic ocular surface inflammation that causes symptoms of severe itch and thick mucoid discharge 1 . Topical corticosteroid eye drops are the mainstay of treatment for attacks due to rapid symptomatic relief, though at the expense of steroid sideeffects. These include cataract development, ocular hypertension, greater infection risks and poorer wound healing 2, 3 . We report a case of steroidinduced glaucoma secondary to injudicious topical corticosteroids use for the treatment of vernal keratoconjunctivitis with resultant severe visual loss.
cAsE REPORt A 20-year-old male, self-reported steroid responder, with a history of vernal keratoconjunctivitis, presented at our centre in May 2006. A steroid responder is an individual who develops high intraocular pressures (IOP) following the administration of steroids.
He had a history of eczema, but did not require steroids for its treatment. His medication only consisted of a combination eye drop of dexamethasone sodium phosphate, chloramphenicol, and tetryzoline hydrochloride (Spersadexoline®), originally prescribed from another centre to control his severe ocular itching. On presentation, Snellen visual acuity was 6/7.5 in both eyes and IOPs by Goldmann applanation tonometry were raised at 38 and 34mmHg (21mmHg is taken as the upper limit of normal) in the right eye and left eye, respectively.
To minimise steroid dose and medically control his IOP, Spersadexoline® was suspended and the patient was commenced on topical cyclosporine A (steroid sparing immunosuppressant), loteprednol (a weaker steroid), olopatadine (an antihistamine and mast cell stabiliser), and ocular hypotensives: timolol 0.5% and latanoprost 0.005%. This was successful until August 2006, when after finding IOP spikes of 48 mmHg (right eye) and 53mmHg (left eye); topical ketorolac (a non-steroidal antiinflammatory drop) and brimonidine and oral acetazolomide (a systemic ocular hypotensive) were also added with good effect.
Over the next six months, his IOP fluctuated. He still maintained a healthy cup-to-disc ratio (CDR) Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 of 0.4 (right eye) and 0.3 (left eye), and full visual fields [standard automated perimetry Humphrey Visual Field Analyzer, SITA (Swedish Interactive Threshold Algorithm) program 24-2 (SAP; Carl Zeiss Meditec, Inc., Dublin, CA)]. A session of IOP phasing (measurement of IOP throughout the day) showed a wide diurnal IOP range (glaucoma patients exhibit greater fluctuations in IOP than normal individuals, which is associated with worsening optic nerve damage) 4 . Each time his IOP was found to be elevated, he was treated with further ocular hypotensives.
Subsequently, the patient confessed that he had continued using Spersadexoline® on his own accord, and discontinued usage prior to ophthalmic review. Within five months, his CDR had increased to 0.7 bilaterally ( Fig. 1 ), which correlated closely with extensive bilateral field loss ( Fig. 2 ). In conjunction with his advanced glaucomatous optic neuropathy, marked field loss, and his young age, this demanded further intervention: sequential trabeculectomy with mitomycin C (MMC) to both eyes. Although he maintained low IOPs in both eyes postoperatively, his CDRs had recalcitrantly worsened to 0.95 (right eye) and 1.0 (left eye), and he developed corresponding severely constricted visual fields. He was registered as legally blind and referred to the Singapore Association of the Visually Handicapped (SAVH) for assistance with At last review in June 2011, despite good visual acuity of 6/9 (right eye) and 6/7.5 (left eye), he had severe tunnel vision ( Fig. 2) and has yet to find a job.
DIscUssION
Vernal keratoconjunctivitis is a recurrent and chronic atopic disease typically affecting young boys in tropical climates 5 . Ocular symptoms include mild to intense pruritis, thick mucoid hyper-secretions, photophobia, foreign body sensation and pain. These may be exacerbated by non-specific trigger factors such as wind, dust, bright light and heat. Ocular findings include conjunctival injection, tarsal and/or limbal papillae that correlate to severity of the attack and thick filamentous discharge. Some patients may have corneal involvement which may range from punctuate epithelial keratitis to frank epithelial erosions, corneal ulcers and scarring. Patients may experience several episodes of inflammation annually although a proportion of patients have no remission from the onset 6 .
Previously believed to be a type 1 hypersensitivity response, recent evidence revealed the pathogenesis to be a complex immunological process. Ocular inflammatory studies have shown abundant expression of T helper cells and their cytokines, corneal fibroblasts and various growth factors in the mechanism of VKC 6 . Avoidance of triggers and conservative measures such as the use of sunglasses and cold compression may be helpful but are often inadequate for symptomatic relief. The multifaceted pathogenesis allows an array of treatment modalities, such as mast-cell stabilisers, immunomodulators, corticosteroids and antihistamines, though often they have to be used in tandem. Steroids are one of the most effective in symptom relief, and being readily available in most general practices, are commonly prescribed. The cyclical nature of vernal keratoconjunctivitis as well as the pronounced discomfort from atopic symptoms, makes it tempting to apply the steroids at each onset of conjunctivitis, including selfadministration against medical advice.
Prolonged corticosteroid application may result in cataract formation or predispose to infections, poor wound healing and steroid-induced glaucoma 7 . Given that glaucoma in its early stages is asymptomatic and even marked sub-acute elevations of IOP may not be painful, patients may trade this off for cessation of their occasionally debilitating ocular itch.
The exact pathophysiology of steroid-induced glaucoma is unknown. It is thought that steroidinduced IOP elevation is secondary to increased aqueous outflow resistance through accumulation of extracellular matrix, increased production of trabecular meshwork inducible glucocorticoid response protein, or the detrimental corticosteroidinduced cytoskeletal changes to the actin microstructure of the trabecular meshwork 8,9 . Glaucoma results from elevated IOP causing retinal ganglion cell apotosis, with several mechanisms postulated: mechanical damage to axons at the optic nerve head, increased expression of glutamate leading to excitotoxicity, TNF-alpha upregulation or increased MMP expression.
The risk of developing steroid-induced glaucoma and its severity is related to the drug's potency, frequency and mode of administration 7 . While locally applied ophthalmic steroid preparations are more infamous culprits, steroid-induced glaucoma may result from topical creams, systemic oral and intravenous, and even inhaled corticosteroids 10, 11 . Studies by Armaly indicated that patients with primary open-angle glaucoma were more susceptible to IOP elevation compared to normal eyes 12, 13 . Important risk factors for steroid-induced ocular hypertension and glaucoma include preexisting POAG, status as a glaucoma suspect, a first-degree relative with POAG, aged under six years old, connective tissue disease, type-1 diabetes mellitus and high myopia [14] [15] [16] [17] [18] . Although cessation of steroid use usually allows resolution of the steroid response within days to a few weeks, studies have shown persistently elevated IOP as long as six months after the injection of intravitreal steroids 19, 20 . Whilst it is possible that the IOP can be normalised with corticosteroid withdrawal, this elevation is sometimes refractory to treatment 21, 22 . Our patient had progressive optic nerve dysfunction despite stopping steroids; hence judicious IOP monitoring is required.
Studies have shown that prolonged fluctuating elevated IOP levels are a risk factor for the development and progression of glaucomatous damage 23, 24 . The Advanced Glaucoma Intervention Proceedings of Singapore Healthcare  Volume 21  Number 1  2012 Study showed that IOP fluctuation was a more significant factor associated with visual field progression compared to mean IOP 25 . The authors speculate that ganglion cell injury from IOP spikes results from acute loading and unloading of stresses, compared to situations of static, high IOP. As the retinal ganglion cells are unable to compensate with acute fluctuating levels of stress, damage occurs. It is possible that our patient's tenacious steroid administration with interspersed break periods between clinic visits caused see-saw IOP changes that induced greater nerve damage in an already compromised optic disc.
Our patient chose the relief of severe itch and discomfort from VKC over treatment of asymptomatic glaucoma. Young patients are known to have a higher risk of uncompliance to glaucoma eye drops 26 . Ocular discomfort may be a greater impediment to the more active lives of younger patients, which may result in the patients favouring treatment of the manifest VKC symptoms.
Crewe et al found that patients with greater visual impairment were more willing to trade life for sight 27 . Another study revealed that blindness causes psychosocial distress with poor maladjustments in areas of education, vocational training, employment and mobility 28 . Our patient suffered severe depression from two chronic, visually debilitating diseases, in addition to frustration at unsuccessful job searching. Blindness has a decisive impact on a young adult psychologically as he first attempts to integrate into society with the realisation that blindness leaves him little occupational opportunities. Job apathy and/or the inability to work may result in economic burden on their family and society.
The hallmark of this case report is the rapidly progressive nature of the patient's glaucomatous damage with surreptitious steroid use causing recurrent IOP spikes. The patient relentlessly progressed, from normal ocular functions at presentation, to severe glaucomatous damage that rendered him legally blind within a period of five months.
Patient education is an important aspect of the management of chronic diseases. The side-effects of corticosteroid use, and the asymptomatic nature of the IOP increases with initially unnoticeable visual field loss should be emphasised prior to starting steroids. Stringent monitoring of intraocular pressures and encouraging compliance to the recommended treatment is quintessential.
cONcLUsION
The use of corticosteroids can lead to blindness and patients requiring prolonged topical corticosteroid therapy should be closely monitored by an ophthalmologist.
